French biophysics pioneer Depixus has launched its inaugural Research Program, offering free access to the company’s unique single molecule interactomics technology.
Depixus’ scalable magnetic force spectroscopy (MFS) platform is the first technology that allows researchers to simultaneously explore dynamic interactions between thousands of individual molecules in near real-time.
The platform is able to analyze interactions between various combinations of RNA, DNA, proteins, and small molecules, providing unprecedented insights into mechanisms of action, binding kinetics and more. It is…
One Nucleus and Life Science Nation unite for the Genesis 2024 and Redefining Early Stage Investments (RESI) Conferences to Amplify Impact on Life Science Innovation.
Boston MA and London UK, 31 July 2024 - One Nucleus and Life Science Nation (LSN) are pleased to announce the co-location of their renowned Genesis 2024 and Redefining Early Stage Investments (RESI) conferences, scheduled to take place on 4 December 2024, in London. The Genesis Conference programme will be at 1 Wimpole Street, and RESI will be at 11 Cavendish Square, allowing attendees to participate in either or both…
Metrion Biosciences' webinar ‘In Vitro Assessment of Cardiac Risk in Drug Discovery’ enabled attendees to learn how an hiPSC-CM model can help provide clear decision-making data for their project team, avoiding costly issues related to QTc and QRS cardiac liabilities in the clinic.
Presentations were received from:
Derek Leishman (VP Translational and Quantitative Toxicology at Eli Lilly and Company) presented the opportunities a sponsor now has available to increase the efficiency and effectiveness of QTc assessment by leveraging the ICH S7B core assays. He also discussed times when the…
Cushman & Wakefield has released its latest Life Sciences Lab Report on the UK's Golden Triangle. The Golden Triangle report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London.
Q2 2024 Take-Up Statistics
• Golden Triangle leasing activity totalled 39,700 sq ft in Q2 2024.
• This lull is typical for the second quarter, with 2024 likely to be the fourth year out of the past six where Q2 has reported the lowest quarterly volume of the year.
• Under-offer space totalled 131,500…
Cambridge, UK, 23 July 2024: Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities.
Following completion of Metrion’s £3.7M equity financing in December 2023, the Company has made several high-profile appointments. Chris’ appointment as CCO further strengthens the…
Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets
Cambridge, UK, 24 July 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive, Steve will guide the expansion of the Company’s commercial operations and implement a robust go-to-market strategy for its Next-Generation Sequencing (NGS)-based DNA…
Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer
Appointment of experienced pre-clinical CRO specialist to support accelerated expansion into key global markets
Cambridge, UK, 23 July 2024: Metrion Biosciences Limited (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing…
Genetically engineered iPSCs offer improved efficiency and cost savings.
AMSBIO has launched a range of genetically engineered Induced Pluripotent Stem Cells (iPSCs) developed to provide improved model fidelity over cell lines and biochemical assays used for drug discovery and cell therapy research.
These iPSC cell lines offer improved efficiency and cost savings compared to animal models, enhancing high-throughput reporter lines, human disease models and toxicity screening. The new range includes iPSCs genetically engineered to express Cas9 either constitutively or upon doxycyclin…
Astex Pharmaceuticals is pleased to share the below news which was today Issued by its collaborator The Institute of Cancer Research, London,
MHRA approves first-in-class breast cancer drug
• MHRA approves first-in-class drug Truqap (capivasertib) in combination with fulvestrant for treating HR-positive, HER-2 negative locally advanced breast cancer with specific biomarker alterations (PIK3CA, AKT1 or PTEN) alterations following recurrence or progression on or after an endocrine based regimen
• Capivasertib was discovered by AstraZeneca subsequent to a collaboration with Astex Pharmaceuticals…